Juliana Jones
Psychiatric/Mental Health · Sikeston, MONPI 1124749775
Payments from drug & device makers
Across 137 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$732
- Otsuka America Pharmaceutical, Inc.$665
- Johnson & Johnson$492
- Teva Pharmaceuticals USA, Inc.$283
- Alkermes, Inc.$169
- E.r. Squibb & Sons, L.L.C.$161
- plus $788 from 12 others
What the payments were for
- Food & beverage$3,24499%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $732 |
| Otsuka America Pharmaceutical, Inc. | 28 | $665 |
| Johnson & Johnson | 15 | $492 |
| Teva Pharmaceuticals USA, Inc. | 5 | $283 |
| Alkermes, Inc. | 9 | $169 |
| E.r. Squibb & Sons, L.L.C. | 7 | $161 |
| Lundbeck LLC | 7 | $138 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $127 |
| Neurocrine Biosciences, Inc. | 6 | $121 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Novartis | 6 | $97 |
| Indivior Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Corium, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$271
- VRAYLAR$229
- Austedo XR$122
- REXULTI$122
- UZEDY$111
How this compares
$3,291 in reported general payments places this provider in the 80th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 42 | $63,960 |
| VraylarCariprazine Hcl | 13 | $18,198 |
| TrintellixVortioxetine Hydrobromide | 31 | $14,499 |
| Aripiprazole | 123 | $6,425 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 226 | $2,753 |
| Clonazepam | 262 | $2,677 |
| Ramelteon | 17 | $2,477 |
| Lurasidone Hcl | 28 | $2,307 |
| Quetiapine Fumarate | 151 | $2,016 |
| Duloxetine Hcl | 111 | $1,682 |
| Mirtazapine | 155 | $1,643 |
| Bupropion XlBupropion Hcl | 100 | $1,448 |
| Buspirone Hcl | 116 | $1,356 |
| Lamotrigine | 124 | $1,324 |
| Olanzapine | 45 | $1,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $665 | $63,96042 claims |
| AbbVieVraylar | $732 | $18,19813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Sikeston
- Amber ToweSikeston$12K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.